by Madaline Spencer | Jun 16, 2026
Carolina Barnett-Tapia, MD, Neuromuscular Neurologist and the University of Toronto, discusses the safety and efficacy of subcutaneous efgartigimod PH20 in ocular myasthenia gravis (oMG). oMG is a neuromuscular disease characterized by autoantibody...
by Madaline Spencer | Jun 15, 2026
Jeff Guptill, MD, Neuromuscular Clinical Development Lead at Argenx, discusses the impact of the Vyvgart (efgartigimod alfa) approval on the myasthenia gravis (MG) community to treat patients with anti-MuSK-Ab positive, anti-LRP4-Ab positive, and/or triple...
by Madaline Spencer | Jun 10, 2026
Abigail Schwaede, MD, Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses results on intravenous efgartigimod in juvenile generalized myasthenia gravis (gMG). gMG is a chronic autoimmune neuromuscular...
by Madaline Spencer | Jun 9, 2026
A study published in the Journal of Clinical Lipidology evaluated maternal and neonatal outcomes of chenodeoxycholic acid (CDCA) treatment during gestation in women with cerebrotendinous xanthomatosis (CTX). CTX is a rare lipid storage disease characterized by the...
by Madaline Spencer | Jun 8, 2026
A study published in The Journal of Pediatrics describes a post hoc analysis of clinical trials evaluating maralixibat in children with Alagille syndrome and its effect on xanthoma severity. Alagille syndrome is a rare genetic disease that affects the liver and other...
